Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Share-based Compensation (2016 - 2026)

Lexaria Bioscience's Share-based Compensation history spans 11 years, with the latest figure at $74895.0 for Q1 2026.

  • Quarterly results put Share-based Compensation at $74895.0 for Q1 2026, down 55.21% from a year ago — trailing twelve months through Feb 2026 was $742650.0 (up 5.35% YoY), and the annual figure for FY2025 was $859494.0, up 74.61%.
  • Share-based Compensation for Q1 2026 was $74895.0 at Lexaria Bioscience, roughly flat from $74895.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $470136.0 in Q2 2025 to a low of $9634.0 in Q3 2023.
  • The 5-year median for Share-based Compensation is $96510.0 (2024), against an average of $134396.6.
  • The sharpest move saw Share-based Compensation plummeted 95.86% in 2023, then surged 901.76% in 2024.
  • Year by year, Share-based Compensation stood at $68776.0 in 2022, then dropped by 21.55% to $53953.0 in 2023, then skyrocketed by 84.26% to $99415.0 in 2024, then dropped by 24.66% to $74895.0 in 2025, then changed by 0.0% to $74895.0 in 2026.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $74895.0, $74895.0, and $122724.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.